MLBCL

(redirected from Mediastinal Large B-Cell Lymphoma)
AcronymDefinition
MLBCLMediastinal Large B-Cell Lymphoma
References in periodicals archive ?
Structural genomic alterations in primary mediastinal large B-cell lymphoma. Leuk Lymphoma 2015; 56(8): 2239-50.
Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children.
Moskowitz et al., "Phase 1b study of PD-1 blockade with pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL)," Blood, vol.
The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.
Gene expression profiling has shown a similarity between the cell lines of primary mediastinal large B-cell lymphoma and classical Hodgkin lymphoma, a disorder with which it shares a number of clinical and laboratory features.
Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study.
Yescarta was the first CAR T cell therapy to be approved by the US Food and Drug Administration for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, and high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.
Preliminary results from a phase 2 study of ADCETRIS in combination with Opdivo (nivolumab) among patients with relapsed or refractory primary mediastinal large B-cell lymphoma (CHECKMATE 436 trial), as well as updated results from an ongoing phase 1/2 study evaluating the combination therapy in relapsed or refractory HL.
Food and Drug Administration has approved KEYTRUDA, the company's anti-PD-1 therapy, for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma, or who have relapsed after two or more prior lines of therapy.
Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am JSurgPathol.
Yescarta is the first chimeric antigen receptor T cell therapy to be indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.
Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 Checkmate 436 Trial.
Full browser ?